REG - SkinBioTherapeutics - Grant of share options

SkinbiotherapeuticsAnnouncement

12/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220112:nRSL1258Ya&default-theme=true

RNS Number : 1258Y  SkinBioTherapeutics PLC  12 January 2022

12 January 2022

 

SkinBioTherapeutics plc

 

 

Grant of share options

 

SkinBioTherapeutics plc (the "Company") a life science company focused on skin
health, announces that it has granted 650,000 options over the ordinary shares
in the Company in accordance with the rules of the Company's EMI share scheme.

 

The options were granted on 11 January 2022 to Geoff Bell, commercial manager
at the Company, at an exercise price of 37.60p, being the closing mid-market
price on 11 January 2022. The options have share price performance and a three
year length of service criteria attached to them.

 

 

-Ends-

For more information please contact:

 SkinBioTherapeutics plc                                 Tel: +44 (0) 161 468 2760

 Stuart J. Ashman, CEO

 Doug Quinn, CFO
 Cenkos Securities Plc (Nominated Adviser & Broker)      Tel: +44 (0) 20 7397 8900

 Giles Balleny, Max Gould (Corporate Finance)

 Michael Johnson, Dale Bellis (Sales)
 Instinctif Partners (financial press)                   Tel: +44 (0) 20 7457 2020

 Melanie Toyne-Sewell / Nathan Billis                    SkinBio@instinctif.com (mailto:SkinBio@instinctif.com)

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix®, is based upon
discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AsixBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis was launched on 29 October - World
Psoriasis Day.

The Company listed on AIM in April 2017 and is based in Manchester, UK. For
more information, visit: www.skinbiotix.com (http://www.skinbiotix.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUAUBRUSUAAAR